The attention deficit hyperactivity disorder market size has grown strongly in recent years. It will grow from $16.29 billion in 2024 to $17.43 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth during the historic period can be attributed to the rising prevalence of ADHD, the increasing incidence of ADHD in children, growing awareness of the condition, higher healthcare expenditure, and government initiatives focused on mental health awareness.
The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $22.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period is expected to be driven by an increasing number of pediatric and adult patients receiving treatment, enhanced healthcare infrastructure, a growing adoption of personalized medicine, greater acceptance of mental health issues, and the rising use of additives and preservatives in children's diets. Key trends during this period include improvements in technology and innovative treatments, advancements in diagnostic and treatment methods, the development of new therapeutic agents, a shift towards non-stimulant medications, and progress in pharmaceutical treatments.
The increasing adoption of personalized medicine is expected to drive the growth of the attention deficit hyperactivity disorder (ADHD) market in the coming years. Personalized medicine is a healthcare approach that customizes treatments based on an individual's genetic, environmental, and lifestyle factors, leading to more precise and effective therapies. The growing interest in personalized medicine can be attributed to advancements in genomic technologies, which allow treatments to be tailored to a person’s genetic profile. This approach significantly enhances the management of ADHD by enabling customized treatment strategies that address an individual's unique characteristics, leading to more targeted and effective interventions. For example, in February 2024, a report from the Personalized Medicine Coalition revealed that personalized medicines accounted for over a third of new FDA drug approvals in 2023, marking the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases, 7 cancer drugs, and 3 other treatments. As a result, the growing adoption of personalized medicine is driving the expansion of the ADHD market.
Companies in the ADHD market are focusing on developing innovative treatments such as extended-release tablets to improve efficacy, enhance patient compliance, and provide long-lasting symptom control. These tablets release medication gradually, providing consistent control of symptoms throughout the day with a single dose. This reduces the need for multiple doses, improving convenience and adherence to the treatment plan for individuals with ADHD. For instance, in February 2022, JAMP Pharma Group, a pharmaceutical company based in Canada, launched Guanfacine XR, a generic version of Takeda Canada Inc.'s INTUNIV XR. Guanfacine XR is a long-acting medication that targets receptors in the brain to improve attention, impulse control, and hyperactivity. Available in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and packaged in 100-count bottles, the drug offers flexibility in treatment.
In September 2024, Collegium Pharmaceutical Inc., a US-based specialty pharmaceutical company, acquired Ironshore Therapeutics Inc. for $525 million. This acquisition is part of Collegium's strategy to expand its portfolio beyond pain management and strengthen its presence in the growing ADHD market, particularly with its differentiated ADHD product, Jornay PM. Ironshore Therapeutics, also based in the US, focuses on developing and commercializing therapies for ADHD.
Major players in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, and Adlon Therapeutics L.P.
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in attention deficit hyperactivity disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the attention deficit hyperactivity disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition marked by persistent inattention, hyperactivity, and impulsivity that disrupt daily functioning. It typically starts in childhood and may continue into adulthood, affecting focus, self-control, and organizational skills. Treatment options include behavioral therapy, medication, and lifestyle changes.
The primary types of ADHD treatment are stimulants and non-stimulants. Stimulants are medications that increase brain activity to improve focus, attention, and impulse control, and are commonly used for managing ADHD. ADHD treatments are categorized by age (children and adults) and gender (male and female). ADHD medications come in various forms, including tablets, capsules, and others, and are distributed through multiple channels such as retail pharmacies, hospital pharmacies, and online pharmacies.
The attention deficit hyperactivity disorder market research report is one of a series of new reports that provides attention deficit hyperactivity disorder market statistics, including the attention deficit hyperactivity disorder industry global market size, regional shares, competitors with the attention deficit hyperactivity disorder market share, detailed attention deficit hyperactivity disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder industry. This attention deficit hyperactivity disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The attention deficit hyperactivity disorder market consists of revenues earned by entities by providing services such as diagnosis, therapy, counselling, medication management, and digital health solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) market also includes sales of medical devices, digital therapeutics, and assistive learning tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $22.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period is expected to be driven by an increasing number of pediatric and adult patients receiving treatment, enhanced healthcare infrastructure, a growing adoption of personalized medicine, greater acceptance of mental health issues, and the rising use of additives and preservatives in children's diets. Key trends during this period include improvements in technology and innovative treatments, advancements in diagnostic and treatment methods, the development of new therapeutic agents, a shift towards non-stimulant medications, and progress in pharmaceutical treatments.
The increasing adoption of personalized medicine is expected to drive the growth of the attention deficit hyperactivity disorder (ADHD) market in the coming years. Personalized medicine is a healthcare approach that customizes treatments based on an individual's genetic, environmental, and lifestyle factors, leading to more precise and effective therapies. The growing interest in personalized medicine can be attributed to advancements in genomic technologies, which allow treatments to be tailored to a person’s genetic profile. This approach significantly enhances the management of ADHD by enabling customized treatment strategies that address an individual's unique characteristics, leading to more targeted and effective interventions. For example, in February 2024, a report from the Personalized Medicine Coalition revealed that personalized medicines accounted for over a third of new FDA drug approvals in 2023, marking the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases, 7 cancer drugs, and 3 other treatments. As a result, the growing adoption of personalized medicine is driving the expansion of the ADHD market.
Companies in the ADHD market are focusing on developing innovative treatments such as extended-release tablets to improve efficacy, enhance patient compliance, and provide long-lasting symptom control. These tablets release medication gradually, providing consistent control of symptoms throughout the day with a single dose. This reduces the need for multiple doses, improving convenience and adherence to the treatment plan for individuals with ADHD. For instance, in February 2022, JAMP Pharma Group, a pharmaceutical company based in Canada, launched Guanfacine XR, a generic version of Takeda Canada Inc.'s INTUNIV XR. Guanfacine XR is a long-acting medication that targets receptors in the brain to improve attention, impulse control, and hyperactivity. Available in various strengths (1 mg, 2 mg, 3 mg, and 4 mg) and packaged in 100-count bottles, the drug offers flexibility in treatment.
In September 2024, Collegium Pharmaceutical Inc., a US-based specialty pharmaceutical company, acquired Ironshore Therapeutics Inc. for $525 million. This acquisition is part of Collegium's strategy to expand its portfolio beyond pain management and strengthen its presence in the growing ADHD market, particularly with its differentiated ADHD product, Jornay PM. Ironshore Therapeutics, also based in the US, focuses on developing and commercializing therapies for ADHD.
Major players in the attention deficit hyperactivity disorder market are Pfizer Inc., Johnson & Johnson, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Neos Therapeutics Inc., Collegium Pharmaceutical Inc., Mallinckrodt Pharmaceuticals plc, Tris Pharma Inc., Arbor Pharmaceuticals LLC, Akili Interactive Labs Inc., Mind Medicine (MindMed) Inc., NeuroSigma Inc., KemPharm Inc., RespireRx Pharmaceuticals Inc., Cingulate Therapeutics LLC, and Adlon Therapeutics L.P.
North America was the largest region in the attention deficit hyperactivity disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in attention deficit hyperactivity disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the attention deficit hyperactivity disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition marked by persistent inattention, hyperactivity, and impulsivity that disrupt daily functioning. It typically starts in childhood and may continue into adulthood, affecting focus, self-control, and organizational skills. Treatment options include behavioral therapy, medication, and lifestyle changes.
The primary types of ADHD treatment are stimulants and non-stimulants. Stimulants are medications that increase brain activity to improve focus, attention, and impulse control, and are commonly used for managing ADHD. ADHD treatments are categorized by age (children and adults) and gender (male and female). ADHD medications come in various forms, including tablets, capsules, and others, and are distributed through multiple channels such as retail pharmacies, hospital pharmacies, and online pharmacies.
The attention deficit hyperactivity disorder market research report is one of a series of new reports that provides attention deficit hyperactivity disorder market statistics, including the attention deficit hyperactivity disorder industry global market size, regional shares, competitors with the attention deficit hyperactivity disorder market share, detailed attention deficit hyperactivity disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder industry. This attention deficit hyperactivity disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The attention deficit hyperactivity disorder market consists of revenues earned by entities by providing services such as diagnosis, therapy, counselling, medication management, and digital health solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) market also includes sales of medical devices, digital therapeutics, and assistive learning tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Attention Deficit Hyperactivity Disorder Market Characteristics3. Attention Deficit Hyperactivity Disorder Market Trends And Strategies4. Attention Deficit Hyperactivity Disorder Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Attention Deficit Hyperactivity Disorder Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Attention Deficit Hyperactivity Disorder Market34. Recent Developments In The Attention Deficit Hyperactivity Disorder Market
5. Global Attention Deficit Hyperactivity Disorder Growth Analysis And Strategic Analysis Framework
6. Attention Deficit Hyperactivity Disorder Market Segmentation
7. Attention Deficit Hyperactivity Disorder Market Regional And Country Analysis
8. Asia-Pacific Attention Deficit Hyperactivity Disorder Market
9. China Attention Deficit Hyperactivity Disorder Market
10. India Attention Deficit Hyperactivity Disorder Market
11. Japan Attention Deficit Hyperactivity Disorder Market
12. Australia Attention Deficit Hyperactivity Disorder Market
13. Indonesia Attention Deficit Hyperactivity Disorder Market
14. South Korea Attention Deficit Hyperactivity Disorder Market
15. Western Europe Attention Deficit Hyperactivity Disorder Market
16. UK Attention Deficit Hyperactivity Disorder Market
17. Germany Attention Deficit Hyperactivity Disorder Market
18. France Attention Deficit Hyperactivity Disorder Market
19. Italy Attention Deficit Hyperactivity Disorder Market
20. Spain Attention Deficit Hyperactivity Disorder Market
21. Eastern Europe Attention Deficit Hyperactivity Disorder Market
22. Russia Attention Deficit Hyperactivity Disorder Market
23. North America Attention Deficit Hyperactivity Disorder Market
24. USA Attention Deficit Hyperactivity Disorder Market
25. Canada Attention Deficit Hyperactivity Disorder Market
26. South America Attention Deficit Hyperactivity Disorder Market
27. Brazil Attention Deficit Hyperactivity Disorder Market
28. Middle East Attention Deficit Hyperactivity Disorder Market
29. Africa Attention Deficit Hyperactivity Disorder Market
30. Attention Deficit Hyperactivity Disorder Market Competitive Landscape And Company Profiles
31. Attention Deficit Hyperactivity Disorder Market Other Major And Innovative Companies
35. Attention Deficit Hyperactivity Disorder Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Attention Deficit Hyperactivity Disorder Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on attention deficit hyperactivity disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for attention deficit hyperactivity disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The attention deficit hyperactivity disorder market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Stimulants; Non-Stimulants2) By Age Group: Children; Adults
3) By Gender: Male; Female
4) By Dosage Form: Tablets; Capsules; Other Dosage Forms
5) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
Subsegments:
1) By Stimulants: Methylphenidate-based Medications; Amphetamine-based Medications; Mixed Amphetamine Salts; Dexmethylphenidate2) By Non-Stimulants: Atomoxetine (Strattera); Guanfacine (Intuniv); Clonidine (Kapvay); Bupropion (Wellbutrin)
Key Companies Profiled: Pfizer Inc.; Johnson & Johnson; AstraZeneca PLC; Novartis International AG; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The companies featured in this Attention Deficit Hyperactivity Disorder market report include:- Pfizer Inc.
- Johnson & Johnson
- AstraZeneca PLC
- Novartis International AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Otsuka Pharmaceutical Co. Ltd.
- Supernus Pharmaceuticals Inc.
- Neos Therapeutics Inc.
- Collegium Pharmaceutical Inc.
- Mallinckrodt Pharmaceuticals plc
- Tris Pharma Inc.
- Arbor Pharmaceuticals LLC
- Akili Interactive Labs Inc.
- Mind Medicine (MindMed) Inc.
- NeuroSigma Inc.
- KemPharm Inc.
- RespireRx Pharmaceuticals Inc.
- Cingulate Therapeutics LLC
- Adlon Therapeutics L.P.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | January 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 17.43 Billion |
| Forecasted Market Value ( USD | $ 22.59 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
